Rhumbline Advisers Raises Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Rhumbline Advisers increased its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 1.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 90,587 shares of the company’s stock after purchasing an additional 1,394 shares during the quarter. Rhumbline Advisers owned 0.19% of Amphastar Pharmaceuticals worth $3,623,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. YHB Investment Advisors Inc. bought a new stake in shares of Amphastar Pharmaceuticals during the first quarter valued at approximately $27,000. Principal Securities Inc. bought a new position in Amphastar Pharmaceuticals in the 4th quarter worth about $34,000. Innealta Capital LLC purchased a new position in shares of Amphastar Pharmaceuticals during the second quarter worth approximately $55,000. Quadrant Capital Group LLC raised its position in Amphastar Pharmaceuticals by 27.8% during the 4th quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock valued at $63,000 after purchasing an additional 223 shares in the last quarter. Finally, Blue Trust Inc. grew its holdings in Amphastar Pharmaceuticals by 23.9% during the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after acquiring an additional 309 shares in the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Piper Sandler cut their target price on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Finally, StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, September 12th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $63.00.

Insiders Place Their Bets

In related news, EVP Rong Zhou sold 4,000 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $48.35, for a total value of $193,400.00. Following the completion of the sale, the executive vice president now owns 118,388 shares of the company’s stock, valued at $5,724,059.80. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, EVP Rong Zhou sold 4,000 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $48.35, for a total value of $193,400.00. Following the completion of the sale, the executive vice president now owns 118,388 shares of the company’s stock, valued at $5,724,059.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Richard K. Prins sold 17,101 shares of the firm’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $43.07, for a total transaction of $736,540.07. Following the sale, the director now owns 33,971 shares of the company’s stock, valued at $1,463,130.97. The disclosure for this sale can be found here. Insiders have sold 37,979 shares of company stock valued at $1,671,307 in the last ninety days. 27.10% of the stock is currently owned by corporate insiders.

Amphastar Pharmaceuticals Price Performance

Shares of Amphastar Pharmaceuticals stock opened at $48.38 on Tuesday. The stock has a market capitalization of $2.36 billion, a P/E ratio of 16.74, a PEG ratio of 0.85 and a beta of 0.82. The business has a 50 day simple moving average of $43.66 and a two-hundred day simple moving average of $42.53. Amphastar Pharmaceuticals, Inc. has a 12 month low of $36.56 and a 12 month high of $65.92. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.52 and a quick ratio of 2.63.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.85 EPS for the quarter, beating the consensus estimate of $0.75 by $0.10. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. The firm had revenue of $182.39 million during the quarter, compared to the consensus estimate of $171.29 million. As a group, analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.71 EPS for the current fiscal year.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.